20240328T023743-0700
emailwire.com
20240329
20240329_1144853
1
urn:newsml:emailwire.com:20240329:20240329_1144853:1
Fri, 29 Mar 2024 00:00:00 -0700
20240329
20240329
Fri, 29 Mar 2024 00:00:00 -0700
akash.r@maximizemarketresearch.com]]>
emailwire.com
20240327
20240327_1144805
1
urn:newsml:emailwire.com:20240327:20240327_1144805:1
Wed, 27 Mar 2024 00:00:00 -0700
20240327
20240327
Wed, 27 Mar 2024 00:00:00 -0700
raviraj.tak@marketsandmarkets.com]]>
emailwire.com
20240327
20240327_1144823
1
urn:newsml:emailwire.com:20240327:20240327_1144823:1
Wed, 27 Mar 2024 00:00:00 -0700
20240327
20240327
Wed, 27 Mar 2024 00:00:00 -0700
akash.r@maximizemarketresearch.com]]>
emailwire.com
20240322
20240322_1144721
1
urn:newsml:emailwire.com:20240322:20240322_1144721:1
Fri, 22 Mar 2024 00:00:00 -0700
20240322
20240322
Fri, 22 Mar 2024 00:00:00 -0700
raviraj.tak@marketsandmarkets.com]]>
emailwire.com
20240311
20240311_1144565
1
urn:newsml:emailwire.com:20240311:20240311_1144565:1
Mon, 11 Mar 2024 00:00:00 -0700
20240311
20240311
Mon, 11 Mar 2024 00:00:00 -0700
raviraj.tak@marketsandmarkets.com]]>
emailwire.com
20240304
20240304_1144477
1
urn:newsml:emailwire.com:20240304:20240304_1144477:1
Mon, 04 Mar 2024 00:00:00 -0800
20240304
20240304
Mon, 04 Mar 2024 00:00:00 -0800
raviraj.tak@marketsandmarkets.com]]>
emailwire.com
20240219
20240219_1144219
1
urn:newsml:emailwire.com:20240219:20240219_1144219:1
Mon, 19 Feb 2024 00:00:00 -0800
20240219
20240219
Mon, 19 Feb 2024 00:00:00 -0800
raviraj.tak@marketsandmarkets.com]]>
emailwire.com
20240207
20240207_1144082
1
urn:newsml:emailwire.com:20240207:20240207_1144082:1
Wed, 07 Feb 2024 00:00:00 -0800
20240207
20240207
Wed, 07 Feb 2024 00:00:00 -0800
agney@marketsandmarkets.com]]>
emailwire.com
20240124
20240124_1143858
1
urn:newsml:emailwire.com:20240124:20240124_1143858:1
Wed, 24 Jan 2024 00:00:00 -0800
20240124
20240124
Wed, 24 Jan 2024 00:00:00 -0800
akash.r@maximizemarketresearch.com]]>
emailwire.com
20240113
20240113_1143743
1
urn:newsml:emailwire.com:20240113:20240113_1143743:1
Sat, 13 Jan 2024 00:00:00 -0800
20240113
20240113
Sat, 13 Jan 2024 00:00:00 -0800
akash.r@maximizemarketresearch.com]]>
emailwire.com
20240109
20240109_1143652
1
urn:newsml:emailwire.com:20240109:20240109_1143652:1
Tue, 09 Jan 2024 00:00:00 -0800
20240109
20240109
Tue, 09 Jan 2024 00:00:00 -0800
raviraj.tak@marketsandmarkets.com]]>
emailwire.com
20240105
20240105_1143636
1
urn:newsml:emailwire.com:20240105:20240105_1143636:1
Fri, 05 Jan 2024 00:00:00 -0800
20240105
20240105
Fri, 05 Jan 2024 00:00:00 -0800
raviraj.tak@marketsandmarkets.com]]>
emailwire.com
20240104
20240104_1143631
1
urn:newsml:emailwire.com:20240104:20240104_1143631:1
Thu, 04 Jan 2024 00:00:00 -0800
20240104
20240104
Thu, 04 Jan 2024 00:00:00 -0800
akash.r@maximizemarketresearch.com]]>
emailwire.com
20231221
20231221_1143581
1
urn:newsml:emailwire.com:20231221:20231221_1143581:1
Thu, 21 Dec 2023 00:00:00 -0800
20231221
20231221
Thu, 21 Dec 2023 00:00:00 -0800
raviraj.tak@marketsandmarkets.com]]>
emailwire.com
20231220
20231220_1143560
1
urn:newsml:emailwire.com:20231220:20231220_1143560:1
Wed, 20 Dec 2023 00:00:00 -0800
20231220
20231220
Wed, 20 Dec 2023 00:00:00 -0800
raviraj.tak@marketsandmarkets.com]]>
emailwire.com
20231218
20231218_1143540
1
urn:newsml:emailwire.com:20231218:20231218_1143540:1
Mon, 18 Dec 2023 00:00:00 -0800
20231218
20231218
Mon, 18 Dec 2023 00:00:00 -0800
20% increase from 2023 to 2024, reaching approximately USD 11 billion. This growth is underscored by the concurrent conduct of more than 1,000 clinical trials. The industry is poised for a substantial influx of approvals, with expectations of as many as 10 to 20 new advanced therapies annually, commencing in 2025. Furthermore, a significant portion of these clinical trials, constituting 33%, are being carried out in Europe. Projections indicate that in 2024 alone, up to 21 cell therapies and as many as 31 gene therapy launches are expected. Notably, this includes over 29 therapies utilizing adeno-associated virus (AAV) technology, highlighting the dynamic and rapidly evolving nature of the CGT field.
Some of the other key trends that the biotech industry is likely to witness in 2024:
Artificial Intelligence (AI) is making significant contributions to various aspects of biotechnology, enhancing research, drug discovery, diagnostics, and personalized medicine. According to recent data, over half of the global healthcare organizations intend to deploy AI plans and widely utilize the technology by 2025. International pharmaceutical/biopharmaceutical and drug development companies will invest more in researching new medications for chronic and oncological diseases.
Gene editing in biotechnology has emerged as a transformative tool, offering unparalleled precision in modifying the genetic code of organisms. Gene editing tools like CRISPR-Cas9 have revolutionized the precision and efficiency of genetic modifications, making it easier for scientists to target specific genes and make desired changes.
Request for Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=153901243
The capacity to leverage big data in biotechnology is poised to emerge as a pivotal factor, impacting critical areas such as drug discovery, drug repurposing, drug safety, functional and structural genomics, proteomics, pharmacogenetics, and pharmacogenomics, among other domains. For example, MassMatrix, a US-based startup, integrates big data, sophisticated algorithms, and artificial intelligence to expedite the process of drug discovery and development.
The MarketsandMarkets Global Biotech Industry Outlook 2024 can help prepare biotech professionals and business leaders for the year ahead.
Mr. Aashish Mehra
1-888-600-6441
raviraj.tak@marketsandmarkets.com]]>
emailwire.com
20231208
20231208_1143503
1
urn:newsml:emailwire.com:20231208:20231208_1143503:1
Fri, 08 Dec 2023 00:00:00 -0800
20231208
20231208
Fri, 08 Dec 2023 00:00:00 -0800
raviraj.tak@marketsandmarkets.com]]>
emailwire.com
20231207
20231207_1143499
1
urn:newsml:emailwire.com:20231207:20231207_1143499:1
Thu, 07 Dec 2023 00:00:00 -0800
20231207
20231207
Thu, 07 Dec 2023 00:00:00 -0800
raviraj.tak@marketsandmarkets.com]]>
emailwire.com
20231130
20231130_1143447
1
urn:newsml:emailwire.com:20231130:20231130_1143447:1
Thu, 30 Nov 2023 00:00:00 -0800
20231130
20231130
Thu, 30 Nov 2023 00:00:00 -0800
dy@maximizemarketresearch.com]]>
emailwire.com
20231123
20231123_1143400
1
urn:newsml:emailwire.com:20231123:20231123_1143400:1
Thu, 23 Nov 2023 00:00:00 -0800
20231123
20231123
Thu, 23 Nov 2023 00:00:00 -0800
raviraj.tak@marketsandmarkets.com]]>